NDA 21169, held by Janssen Pharms. Galantamine Hydrobromide.
As of Nov 15, 2026, NDA 21169 (Razadyne), held by Janssen Pharms, was first approved by FDA on Feb 28, 2001, with 20 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 2001 | Original applicationNew molecular entity · Standard review | Approved |
| RazadyneEQ 4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · tablet;oral | Galantamine Hydrobromide | DiscontinuedReference drug |
| RazadyneEQ 8MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · tablet;oral | Galantamine Hydrobromide | DiscontinuedReference drug |
| RazadyneEQ 12MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · tablet;oral | Galantamine Hydrobromide | DiscontinuedReference drug |
| Aug 3, 2021 | Supplement 35Labeling · Standard review | Approved | |
| Mar 20, 2020 | Supplement 34Labeling · Standard review | Approved | |
| Feb 21, 2020 | Supplement 33Labeling · Standard review | Approved | |
| Feb 14, 2017 | Supplement 32Labeling · Standard review | Approved | |
| Dec 15, 2015 | Supplement 31Labeling · Standard review | Approved | |
| Feb 9, 2015 | Supplement 30Labeling · Standard review | Approved | |
| Jun 28, 2013 | Supplement 24Labeling · Standard review | Approved | |
| May 21, 2013 | Supplement 28Manufacturing · Standard review | Approved | None posted |
| Mar 1, 2012 | Supplement 26Labeling · Standard review | Approved | |
| Mar 1, 2012 | Supplement 17Labeling · Standard review | Approved | |
| Mar 1, 2012 | Supplement 16Labeling · Standard review | Approved | |
| Apr 27, 2006 | Supplement 14Labeling · Standard review | Approved | |
| Apr 27, 2006 | Supplement 13Labeling · Standard review | Approved | |
| Apr 27, 2006 | Supplement 12Labeling · Standard review | Approved | |
| Apr 27, 2006 | Supplement 10Labeling · Standard review | Approved | |
| May 2, 2005 | Supplement 11Labeling · Standard review | Approved | |
| Sep 3, 2003 | Supplement 7Labeling · Standard review | Approved | |
| Jul 31, 2002 | Supplement 4Manufacturing · Standard review | Approved | None posted |
| Apr 19, 2002 | Supplement 3Labeling · Standard review | Approved | |
| Aug 15, 2001 | Supplement 1Manufacturing · Standard review | Approved | None posted |
| Feb 28, 2001 | Original applicationNew molecular entity · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters